Park Square has placed Maya Kotturi as Vice President, Preclinical Development at Infinimmune, a pioneering, venture-backed biotechnology company reinventing the way that antibody therapeutics are discovered and developed. 

Kotturi brings significant experience in antibody drug development. She previously served as Executive Director, Translational Research at IGM Biosciences, a publicly traded company developing antibody therapeutics. She joined the company in 2019 as Director, Pharmacodynamics and Biomarkers, and was promoted to Senior Director, Translational Research in 2022. During her tenure with IGM, she helped to author eight INDs and oversaw a team of 12 scientists. 

Prior, she held roles of increasing responsibility at Compugen, a biotherapeutics company developing cancer immunotherapies, ultimately serving as Associate Director, Immuno-Oncology. Previously, she was a Senior Scientist II, and she joined the company as a Senior Scientist. Earlier, she was a Senior Scientist at Pfizer, and she spent time at the La Jolla Institute for Allergy and Immunology where she initially served as a Post-Doctoral Fellow and subsequently as a Research Scientist. Kotturi began her career as a Quality Control Manager at Nventa Biopharmaceuticals Corporation. 

Kotturi received her Ph.D. in Microbiology and Immunology from the University of British Columbia and her B.S. in Biochemistry and Microbiology from the University of Victoria.